NEW YORK, NY–(Marketwired – Mar 18, 2015) – “New To The Street” just completed a full 11 minute in-depth interview with George Yu, President and CEO of Accurexa Inc. (OTCQB: ACXA) and its BranchPoint Device.
In this interview George Yu discussed the development and features of the “BranchPoint” device. This is the first installment of a six part series set to be aired nationwide to over 95 million homes on the History Channel on Thursday, March 26 at 6:30am. It will also be aired in New York on WPXN at 7:00am on Monday, March 23, 2015.
“This device has the potential to improve the outcome of brain therapy and enable direct delivery of drugs to the brain,” says Vince Caruso, producer, “New To The Street.”
“We are excited to be featured by ‘New To The Street’ in this first installment. Our ‘BranchPoint’ device has the potential to directly deliver stem cells to patients with neurodegenerative diseases such as Parkinson’s, or chemotherapy to patients with brain cancer. In the latter case, we are developing our ACX-31 program to deliver temozolomide which is a generic, approved chemotherapy drug and used to generate US sales of $420 million and global sales of $910 million under its brand name Temodar in 2012 before it became generic,” says George Yu, President & CEO of Accurexa, Inc.
About New To The Street
New To The Street paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis and public company profiles. New To The Street is produced by FMW Media Works Corp., a leading provider of business profiles and corporate special programming, and airs as paid-programming weekly in New York and monthly nationwide reaching more than 105 million homes, visit www.newtothestreet.com.
The Company is focused on developing and commercializing novel neurological therapies based on its proprietary BranchPoint device delivering therapeutics directly into specific regions of the brain. The BranchPoint device can deliver therapeutics through the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. Clinicians can “tailor” therapeutic delivery to individual patient anatomy and specific disease targets, which may enhance the efficacy of therapies.
The BranchPoint device may also give physicians more precise control of the volume of therapeutics delivered and could ensure that therapeutics delivered into the brain would stay in the brain, avoiding the problem of reflux out to the brain surface. This modern and “easy to use” technology may allow “real-time” monitoring of therapeutic delivery under interventional MRI guidance (iMRI), which could improve the accuracy of therapeutic delivery, reduce the risk of complications, and increase patient safety.
The BranchPoint device was developed at the University of California, San Francisco (UCSF) with $1.8 million in funding from the California Institute for Regenerative Medicine (CIRM). It is based on a neurosurgical delivery platform that the Company has exclusively licensed from UCSF. It can potentially enable new approaches to neurological therapy and be modified for the delivery of a broad range of novel therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors. Additional information about the Company may be found on its website, www.accurexa.com.
Safe Harbor Statement
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the ability of the Company to successfully develop and commercialize novel neurological therapies based on its BranchPoint device, ACX-31 and execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.